US Market Report for Temporary Artificial Heart Replacement Devices 2018; New Report Launched

DrugPipeline.net has announced the addition of “US Market Report for Temporary Artificial Heart Replacement Devices 2018 - MedCore” research report to their website www.DrugPipeline.net


Bangalore, India -- (SBWIRE) -- 01/05/2018 -- SynCardia's CardioWest™ was the world's first FDA-approved total artificial heart. It received FDA approval in October 2004 following a ten-year pivotal clinical study. The CardioWest™ was originally designed as a permanent replacement heart, but was approved as a bridge-to-transplant device for patients dying due to irreversible end-stage biventricular failure in which both the left and right ventricles of their hearts are failing.

SynCardia's CardioWest™ is now marketed as the SynCardia Total Artificial Heart™. As of 2017, SynCardia's Total Artificial Heart™ has been implanted in over 1,700 cases worldwide, with over 500 implants in the United States. It is estimated to have accounted for more than 600 patient years of extended life on the device.

Artificial heart devices can be temporary or permanent mechanical devices that are designed to replace the function of a biological heart. The term "artificial heart" should not be used for describing ventricular assist devices (VADs). VADs are pumps that assist the heart but are not designed to replace it.

Instead, they are used in collaboration with a patient's heart. An artificial heart is also distinct from a cardiopulmonary bypass machine (CPB), which is an external device used for providing the functions of both the heart and lungs. CPBs are only used for a few hours at a time, most commonly during heart surgery. Artificial hearts were originally intended to be a permanent replacement for the biological human heart.

Spanning over 381 pages "US Market Report for Temporary Artificial Heart Replacement Devices 2018 - MedCore" report covers Executive Summary, U.S. Cardiac Surgery And Heart Valve Device Market Overview, Competitive Analysis, Market Trends, Market Developments, Research Methodology, Disease Overview, Product Portfolio, Temporary Artificial Heart Replacement Device Market, Appendix. This report Covered Companies - Edwards Lifesciences, St. Jude Medical, Medtronic, Maquet, Abiomed, HeartWare Inc., Sorin Group, Terumo, Abbott Laboratories, Teleflex Medical, Cardiac Assist, AtriCure, W.L. Gore, SynCardia, Boston Scientific, Cryolife, Others include: Berlin Heart, Cardica, Chase Medical, Genesee Biomedical, Karl Storz, LifeNet Health, Microline Surgical, Novadaq, On-X, Saphena Medical, SentreHeart, Vitalitec, etc.

For more information Visit at: https://www.drugpipeline.net/idata-research/us-market-report-temporary-artificial-heart-replacement-devices-2018-medcore

Find all Pharma and Healthcare Reports at - http://www.drugpipeline.net/catalog/pharma-healthcare

Related Reports;

US Market Report for Off-Pump Coronary Artery Bypass Devices 2018 - MedCore - Visit at - https://www.drugpipeline.net/idata-research/us-market-report-pump-coronary-artery-bypass-devices-2018-medcore-0

US Market Report for Anastomosis Assist Devices 2018 - MedCore - Visit at - https://www.drugpipeline.net/idata-research/us-market-report-anastomosis-assist-devices-2018-medcore

About DrugPipeline.net
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.